Naidoo N, Cooperman B S, Wang Z M, Liu X Z, Rubin H
Department of Chemistry, University of Pennsylvania, Philadelphia 19104, USA.
J Biol Chem. 1995 Jun 16;270(24):14548-55. doi: 10.1074/jbc.270.24.14548.
The human serum serine protease inhibitor (serpin) alpha 1-antichymotrypsin (ACT) appears to be unique among serpins in its ability to bind to double-stranded DNA. Using site-directed mutagenesis and chemical modification, a tri-lysine sequence (residues 210-212) falling within a solvent exposed loop and the C-terminal peptide containing two lysines (residues 391 and 396) were shown to be important for DNA binding. Mutation of residues 210-212 from lysines to either glutamates or threonines abolished DNA binding. The Lys210-Thr211-212 and Thr210-Th4(211)-Lys212 variants displayed reduced affinity for DNA, especially at higher ionic strength. Limited acetylation of rACT with acetic anhydride led to loss of DNA binding and, conversely, DNA protected rACT from acetylation. A combination of CNBr digestion, peptide separation, and peptide sequencing identified Lys396, two residues from the C terminus, as the most reactive lysine in rACT. Acetylation of Lys396 is strongly decreased in the presence of DNA. The double mutant K391T/K396T-rACT had very little affinity for DNA. The epsilon-amines of lysines 210-212 are 8-15 A across a cleft from the epsilon-amines in Lys391 and Lys396, and together these two elements may form an unusual DNA binding domain. Attempts to isolate a DNA sequence to which ACT binds specifically have been unsuccessful to date, raising the possibility that nonspecific binding of ACT to DNA suffices to account for the ACT found in certain cell nuclei. ACT variants not binding to double-stranded DNA retain ACT protease inhibitory activity, a potentially important result for the use of ACT variants as therapeutic agents.
人血清丝氨酸蛋白酶抑制剂(丝氨酸蛋白酶抑制剂)α1-抗糜蛋白酶(ACT)在与双链DNA结合的能力方面,在丝氨酸蛋白酶抑制剂中似乎是独特的。通过定点诱变和化学修饰,发现位于溶剂暴露环内的一个三赖氨酸序列(第210 - 212位残基)以及含有两个赖氨酸的C末端肽(第391和396位残基)对DNA结合很重要。将第210 - 212位残基的赖氨酸突变为谷氨酸或苏氨酸会消除DNA结合。Lys210 - Thr211 - 212和Thr210 - Thr211 - Lys212变体对DNA的亲和力降低,尤其是在较高离子强度下。用乙酸酐对重组ACT进行有限乙酰化导致DNA结合丧失,相反,DNA保护重组ACT不被乙酰化。结合溴化氰消化、肽分离和肽测序,确定C末端的两个残基Lys396是重组ACT中反应性最强的赖氨酸。在DNA存在下,Lys396的乙酰化显著降低。双突变体K391T/K396T - rACT对DNA几乎没有亲和力。赖氨酸210 - 212的ε-氨基与Lys391和Lys396中的ε-氨基在一个裂隙中相隔8 - 15埃,这两个元件可能共同形成一个不寻常的DNA结合结构域。迄今为止,试图分离ACT特异性结合的DNA序列均未成功,这增加了ACT与DNA的非特异性结合足以解释在某些细胞核中发现的ACT的可能性。不与双链DNA结合的ACT变体保留了ACT蛋白酶抑制活性,这对于将ACT变体用作治疗剂可能是一个重要结果。